(Q44622043)

English

Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results

scientific article published on 3 December 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

Lydia Giannitrapani

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24297581%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Giuseppe Salvaggio

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24297581%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Giuseppe Cabibbo

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24297581%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Giuseppe Cabibbo

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24297581%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

author name string

Alessandro Furlan

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24297581%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Francesco Agnello

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24297581%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Daniele Marin

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24297581%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Chiara Genco

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24297581%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Massimo Midiri

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24297581%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Roberto Lagalla

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24297581%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Giuseppe Brancatelli

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24297581%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

publication date

3 December 2013

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Radiologia medica, rivista mensile

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24297581%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

119

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24297581%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24297581%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

215-221

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24297581%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

https://scigraph.springernature.com/pub.10.1007/s11547-013-0332-5

0 references

Management of hepatocellular carcinoma: An update

1 reference

https://api.crossref.org/works/10.1007%2FS11547-013-0332-5

21 January 2018

Sorafenib in liver cancer--just the beginning

1 reference

https://api.crossref.org/works/10.1007%2FS11547-013-0332-5

21 January 2018

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS11547-013-0332-5

21 January 2018

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS11547-013-0332-5

21 January 2018

Response to treatment series: part 1 and introduction, measuring tumor response--challenges in the era of molecular medicine

1 reference

https://api.crossref.org/works/10.1007%2FS11547-013-0332-5

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1007%2FS11547-013-0332-5

21 January 2018

Evaluation of response in malignant tumors treated with the multitargeted tyrosine kinase inhibitor sorafenib: a multitechnique imaging assessment

1 reference

https://api.crossref.org/works/10.1007%2FS11547-013-0332-5

21 January 2018

Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS11547-013-0332-5

21 January 2018

Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT.

1 reference

https://api.crossref.org/works/10.1007%2FS11547-013-0332-5

21 January 2018

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS11547-013-0332-5

21 January 2018

Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib

1 reference

https://api.crossref.org/works/10.1007%2FS11547-013-0332-5

21 January 2018

Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib

1 reference

https://api.crossref.org/works/10.1007%2FS11547-013-0332-5

21 January 2018

Assessment of the treatment response of HCC.

1 reference

https://api.crossref.org/works/10.1007%2FS11547-013-0332-5

21 January 2018

CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings

1 reference

https://api.crossref.org/works/10.1007%2FS11547-013-0332-5

21 January 2018

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

1 reference

https://api.crossref.org/works/10.1007%2FS11547-013-0332-5

21 January 2018

Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST).

1 reference

https://api.crossref.org/works/10.1007%2FS11547-013-0332-5

21 January 2018

Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1007%2FS11547-013-0332-5

21 January 2018

Dynamic contrast-enhanced MRI analysis of perfusion changes in advanced hepatocellular carcinoma treated with an antiangiogenic agent: a preliminary study

1 reference

https://api.crossref.org/works/10.1007%2FS11547-013-0332-5

21 January 2018

Changes in Tumor Density in Patients with Advanced Hepatocellular Carcinoma Treated with Sunitinib

1 reference

https://api.crossref.org/works/10.1007%2FS11547-013-0332-5

21 January 2018

Response to treatment series: part 2, tumor response assessment--using new and conventional criteria

1 reference

https://pubmed.ncbi.nlm.nih.gov/24297581

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44622043&oldid=2029548970"